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TNF-α-induced Inflammation 
Stimulates Apolipoprotein-A4 via 
Activation of TNFR2 and NF-κB 
Signaling in Kidney Tubular Cells
Hyung Ho Lee1,4, Young In Cho1,2, Sook Young Kim1, Young Eun Yoon5, Kyung Sup Kim2,3,  
Sung Joon Hong1,2 & Woong Kyu Han  1,2
Apo-A4 expression was increased in tissues from chronic kidney disease (CKD) patients compared 
to that in normal kidney tissue. We determined the association of apo-A4 and its regulatory signals 
following acute kidney injury and elucidated the effects of apo-A4 on cell signaling pathways related to 
kidney injury in vitro and in vivo. Tumor necrosis factor (TNF)-α, which causes inflammatory cell injury, 
induced significantly increased expression of apo-A4 protein levels, and these levels were related to 
pro-inflammatory acute kidney injury in human kidney cells. Apo-A4 expression was also increased in 
experimented rat kidney tissues after ischemic reperfusion injury. The expression of tumor necrosis 
factor receptor (TNFR) 2 was increased in both kidney cell lines and experimented rat kidney tissues 
following acute kidney injury. The expression of apo-A4 and TNFR2 was increased upon treatment with 
TNF-α. Immunohistochemistry revealed positive apo-A4 and TNFR2 staining in ischemic reperfusion 
injury rat kidneys compared with levels in the sham operation kidneys. After neutralization of TNF-α, 
NF-κB expression was only observed in the cytoplasm by immunofluorescence. Therefore, the apo-A4 
expression is increased by stimulation of injured kidney cells with TNF-α and that these effects occur via 
a TNFR2-NFκB complex.
In human kidney, apo-A4 is localized to the proximal and distal tubular cells. Apo-A4 is filtered by the glomer-
uli in its lipoprotein-unbound state and then taken up by proximal tubular cells for degradation1. Apo-A4 is 
associated with several kidney diseases (nephrotic syndrome vs. non-nephrotic syndrome), and expression in 
kidney tubular cells suggests that apo-A4 is metabolized in the kidney2, 3. Creatinine clearance correlates neg-
atively with serum apo-A4 expression in kidney diseases. Moreover, patients with a tubular type of proteinuria 
have significantly higher amounts of apo-A4 in their urine than those with a pure glomerular type of proteinuria 
and controls4. Apo-A4 levels increase significantly with decreasing glomerular filtration rates and are elevated in 
early stages of chronic kidney disease (CKD). Higher concentrations of plasma apo-A4 serve as a good predictor 
for the progression of kidney disease5, 6. Therefore, apo-A4 levels represent a novel predictor for kidney disease 
progression3. Elevated apo-A4 levels in response to impaired kidney function may enhance the removal of cho-
lesterol from mesangial cells, but this has yet to be confirmed7. Significantly higher apo-A4 levels are observed in 
the blood plasma and urine of CKD patients, and apo-A4 accumulation increases significantly during the initial 
phase of the disease2, 8. Continuous apo-A4 accumulation following kidney injury leads to amyloidosis, which 
is characterized by amyloid deposits in body tissues and organs4. Therefore, apo-A4 accumulation may have an 
adverse impact on in kidney cell recovery. These findings suggest that apo-A4 levels increase as kidney injury pro-
gress and that apo-A4 influences the recovery of injured kidney cells. To date, the molecular signals involved in 
the association between apo-A4 and kidney injury have not been investigated. Therefore, the aim of this study was 
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to demonstrate the association of apo-A4 and regulatory signals of apo-A4 following acute kidney injury (AKI) 
and elucidate the effects on cell signaling pathways related to kidney injury in vitro and in vivo.
Results
Localization and expression of apo-A4 in kidney cell lines and human kidney tissues. To inves-
tigate the expression of apo-A4 in the kidney, we used two kidney cancer cell lines (caki-1 and caki-2) and two 
normal kidney cell lines (HK-2 and HEK-293). We measured apo-A4 expression levels in these cells using west-
ern blotting (Fig. 1A). We observed apo-A4 protein expression in all four kidney cell lines. Also, we examined 
apo-A4 expression in normal kidney and CKD tissues by immunohistochemistry (IHC) using a mouse anti-
apo-A4 antibody. IHC revealed apo-A4 expression in normal and CKD tissues (Fig. 1B). We detected apo-A4 
expression in the tubules as well as in the glomeruli, and interestingly, the intensity of apo-A4 expression in CKD 
tissue was stronger than in healthy kidney tissue.
Apo-A4 expression in kidney cell lines following renal injury model. To determine which type 
of renal injury model affects apo-A4 expression in kidney cells, we exposed human kidney cells to conditions 
known to induce an AKI. We incubated Caki-1, HK-2, and HEK293 cells in a hypoxic chamber for 72 h (Fig. 2A); 
yet, we detected no significant expression of apo-A4 in any of these cell-lines as a result. We induced chemical 
hypoxia using CoCl2 (0, 100, and 200 µM) for 8, 16, and 24 h in HK-2 cells, but these conditions also had no 
effect on apo-A4 expression in these cell types (Fig. 2B). Also, we treated HK-2 cells with the nephrotoxic can-
cer drug cisplatin; the calcium ionophore A23187, which induces calcium influx that causes apoptosis; and the 
pro-inflammatory cytokines TNF-α and IL-1β, which are known to cause inflammatory injury9, 10. Following 
treatment, we measured apo-A4 protein expression levels by western blotting (Fig. 2C). While cisplatin and IL-1β 
failed to modify the expression of apo-A4 in these cells, TNF-α induced significantly increased expression of 
apo-A4. Although we observed an increase in apo-A4 following treatment with A23187, this change was not 
significant. Immunofluorescence assays revealed an increase in apo-A4 expression 24 h after TNF-α treatment 
compared with levels in the untreated control group (Fig. 2D). Furthermore, the expression of apo-A4 in the 
nucleus of HK-2 cells was increased in accord with TNF-α treatment. Thus, of the renal injury agents tested, only 
TNF-α significantly affects the expression of apo-A4.
Inflammatory AKI induced by TNF-α increased apo-A4 Expression. To examine whether AKI 
induced by TNF-α increased apo-A4 expression in vivo, we induced ischemic reperfusion injury in rat kid-
neys (Fig. 3A)7. We removed kidney tissue 48 h after reperfusion and isolated protein lysates to measure apo-A4 
expression levels by western blotting. Apo-A4 protein expression was elevated in ischemic reperfusion injury 
tissue compared with levels in control tissue (Fig. 3B). Also, we isolated serum samples from these rats and con-
firmed the increased apo-A4 levels by enzyme-linked immunosorbent assay (ELISA). Data presents 10 samples, 
Figure 1. Kidney cell lines and human kidney tissues expressed apo-A4. (A) Endogenous apo-A4 protein 
expression was measured in Caki-1, Caki-2, HK-2, and HEK-293 cells by western blotting. The loading control 
was α-tubulin. (B) IHC of apo-A4 in Formalin-fixed, paraffin-embedded human normal and CKD kidney 
tissue.
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Figure 2. Effect of renal injury model expressed apo-A4 in kidney cell lines. (A) Hypoxic cell injury; 
HIF-1α and apo-A4 expression in Caki-1, HK-2, and HEK-293 cells exposed to hypoxia for 72 h. (B) 
Chemical cell injury; HIF-1α and apo-A4 expression in HK-2 cells treated with different concentrations 
of CoCl2 (0, 100, and 200 µM) for 8, 16, and 24 h. (C) Cytotoxic cell injury and cytokaine cell injury; Apo-
A4 expression in HK-2 cells treated with cisplatin (0, 10, 20, and 30 µM), A23187 (0, 0.1, 0.5, and 1 μg/
ml), TNF-α (0, 50, 100, and 200 ng/ml), and IL-1β (0, 50, 100, and 200 ng/ml) for 24 h (see Supplementary 
Figs S1, 2 and 3). (D) Immunofluorescence assay showing localization of apo-A4 (red) in HK-2 cells after 
24 h of treatment with TNF-α.
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and were shown as mean ± SEM and analyzed by students t-test (*P ≤ 0.05; Fig. 3C). Together, these findings 
indicate that apo-A4 expression is increased by inflammatory AKI in vitro and in vivo.
Inflammatory AKI induced by TNF-α increases apo-A4 via TNF Receptor 2 (TNFR2). Expression 
of TNFR2 increases in tubular epithelial cells during ischemic reperfusion injury11. Therefore, we measured the 
expression of apo-A4 and TNFR2 upon induction of AKI. The expression of apo-A4 and TNFR2 were increased 
upon treatment of TNF-α as assessed by western blotting (Fig. 4A). Also, we detected the expression of apo-A4 
and TNFR2 by IHC in rat kidney tissue. Furthermore, IHC revealed positive apo-A4 and TNFR2 staining in 
ischemic reperfusion injury rat kidneys compared with the sham operation kidneys (Fig. 4B). These experi-
ments revealed a positive correlation between the expression of apo-A4 and TNFR2 following treatment with the 
pro-inflammatory cytokine TNF-α.
Increased apo-A4 expression caused by inflammatory AKI is associated with the NF-κB 
Complex. The NF-κB complex plays a major role in inflammation12. We treated HK-2 cells with TNF-α, 
TNF-α antibody and then measured IκB and apo-A4 expression by western blotting. We observed an inverse 
correlation between apo-A4 and IκB expression levels (Fig. 5A). Western blotting revealed expression in apo-A4 
increased by TNF-α concentration. When 100, 200 ng/ml of TNF-α were administered, apo-A4 increased by 1.45 
and 1.2. Moreover, apo-A4 levels decreased significantly to 0.41 for TNF-α antibody treated group. The expres-
sion of IκB was similar to control when treated TNF-α antibody (Fig. 5A). Also, we neutralized TNF-α using a 
specific TNF-α antibody and then examined NF-κB localization using an immunofluorescence assay. NF-κB 
expression was only observed in the cytoplasm after neutralization of TNF-α in comparison with localization of 
this cytokine in untreated HK-2 cells (Fig. 5B). This finding suggests that NF-κB translocation is promoted by 
TNF-α, which elevates apo-A4 expression levels.
Discussion
AKI occurs in the initial stages of kidney disease and is followed by CKD13. Previous work has demonstrated 
that apo-A4 expression in kidney was significantly elevated during AKI and that serum apo-A4 increases during 
the earliest phases of renal insufficiency3–5. We had previously shown that apo-A4 expression levels are strongly 
reduced in pig kidneys when ischemic preconditioning was performed prior to renal ischemic reperfusion 
injury14. Also, we found that the down-regulation of apo-A4 expression affected the recovery of kidney cells from 
ischemic reperfusion injury14. Thus, we hypothesized that kidney cell injury is influenced by increased apo-A4 
expression level just after AKI. To test this hypothesis, we examined the role of apo-A4 and the apo-A4 associated 
pro-inflammatory pathway under conditions of AKI.
First, we observed endogenous apo-A4 expression levels in kidney cell lines and tissues. Apo-A4 has been 
reported to be expressed in proximal and distal tubular cells, capillaries, and blood vessels but not in the glomer-
uli of normal kidneys; however, we observed apo-A4 expression in kidney tubular cells as well as in the glomeruli 
of normal and injured kidney tissues1, 4. We anticipated apo-A4 accumulation in the kidney during ischemic rep-
erfusion injury, and indeed, apo-A4 expression levels were elevated in CKD tissue compared with those in normal 
kidney tissue4. This result indicates that apo-A4 is up-regulated in response to kidney injury. The accumulation 
Figure 3. Inflammatory AKI induced by TNF-α increased apo-A4 expression in vivo. (A) Graphical 
presentation of in vivo experiment method with male SD rat. (B) Expression of apo-A4 protein detected by 
western blotting of kidney tissue from an ischemic reperfusion injury rat model. (C) Apo-A4 expression in rat 
plasma measured by ELISA. Results represent the mean (±SEM) of ten independent experiments (n = 10). The 
statistical signification was marked as * for p < 0.05 compared with the control.
www.nature.com/scientificreports/
5ScIentIfIc RepoRTs | 7: 8856  | DOI:10.1038/s41598-017-08785-2
of apo-A4 has been reported in the blood plasma and urine of CKD patients during initial phases of the disease, 
suggesting that apo-A4 expression can predict the progression of kidney disease2, 3, 5, 8.
Also, we induced injury in human kidney cells using different AKI conditions. AKI is caused by decreased 
renal blood flow (ischemia of kidney tissue), exposure to harmful substances, inflammatory processes, or urinary 
tract obstructions, which impede the flow of urine15, 16. To mimic renal ischemia, we exposed human kidney cells 
to physical and chemical hypoxic conditions.
Additionally, we induced nephrotoxicity by treating kidney cells with cisplatin and induced apoptosis by treat-
ment of kidney cells with the calcium ionophore (A23187), which increases intracellular Ca2+ levels17, 18. We did 
not observe any correlation between apo-A4 expression and renal injury model induced by cisplatin and A23187.
Finally, we investigated the effect of inflammatory injury on apo-A4 expression. Inflammatory processes 
comprise a critical response to pathogenic infection; however, the excessive production of inflammatory 
cytokines, such as TNF-α and IL-1β, may induce cell injury. TNF-α is a group of pro-inflammatory cytokines 
implicated in a wide variety of biological processes. This cytokine is produced by multiple cell types, including 
macrophages, lymphocytes, fibroblasts, and keratinocytes, as a response to inflammation, infection, and other 
environmental stresses17, 19. We found that the increase in apo-A4 expression level caused by TNF-α was related 
to pro-inflammatory AKI in human kidney cells. In vivo, we induced ischemic reperfusion injury in rat kidneys 
to investigate the effect of apo-A4 expression on specific conditions of inflammatory kidney injury. We invoked 
ischemic reperfusion injury using the clamping of renal hilar vessels (renal artery and renal vein) to elicit an 
inflammatory reaction in rat kidneys7. We provoked reperfusion injury and isolated protein lysates to measure 
apo-A4 expression levels by western blotting. Apo-A4 protein expression was elevated in ischemic reperfusion 
injury tissue compared with levels in control tissue (Fig. 3B). Also, we isolated serum samples from these rats and 
confirmed the increased apo-A4 levels by enzyme-linked immunosorbent assay (ELISA). Data presents 10sam-
ples were shown statistically significant (*P ≤ 0.05; Fig. 3C). In vitro and in vivo, these findings indicate that 
inflammatory AKI increases apo-A4 expression.
TNFR1 acts like cell death, altered target gene transcription, and cytokine production. TNFR2 interacts 
either in cooperation with or independently with TNFR1, acts as cell proliferation and cell survival. TNFR2 
may have an antiapoptotic effect acting through an NF-kB pathway that results in exacerbated expression of 
several inflammatory mediators20. TNFR2 plays an important role during the inflammatory process12, 19. This 
receptor was up-regulated during intestinal inflammation, and concordantly, less intestinal inflammation was 
observed in TNFR2-deficient mice11, 19, 21. We demonstrated that apo-A4 expression was increased during inflam-
matory injury stimulated by TNF-α and that the expression of TNFR2 was increased in both kidney cell lines and 
experimented rat kidneys following AKI. Therefore, inflammatory injury stimulated by TNF-α induced TNFR2 
activation.
Figure 4. Inflammatory AKI induced by TNF-α increased apo-A4 expression via TNFR2. (A) HK-2 cells were 
treated with different concentrations of TNF-α (0, 50, and 200 ng/ml) for 24 h. Apo-A4 protein expression was 
detected by western blotting. (B) Apo-A4 and TNFR2 immunohistochemistry on formalin-fixed, paraffin-
embedded tissue from ischemic reperfusion injury rat kidneys.
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TNF-α-mediated activation of the NF-κB complex initiates phosphorylation and proteasomal degradation of 
IκB within the cytoplasm, promoting nuclear translocation of the p65 subunit of NF-κB and enabling heterod-
imeric NF-κB to enter the nucleus. In the nucleus, NF-κB binds to enhancers of its target genes12, 22, 23. In our 
research, TNF-α inhibited IκB and activated NF-κB. Also, the expression of Apo-A4 decreased when IκB activity 
was high (Fig. 5A). TNF-α was found to be a major factor in the expression of apo-A4, because of the apo-A4 
lower than the normal control when TNF-α antibody was administered.
We conduct an additional experiment that NF-κB regulates apo-A4 expression. It has reported that NF-κB 
inhibitors attenuate the inflammatory response in injured kidney animal model24, 25. Pyrrolidine dithio-carbamate 
ammonium (PDTC) is known to inhibit the NF-κB system and attenuated renal damage and inflammation24, 25. 
Apo-A4 was decreased when HK-2 cell treated by PDTC, compared to control group (Supplementary Fig. S4A,B). 
Apo-A4 was increased in the AKI model treated with TNF-α. The administration of TNF-α and PDTC in HK-2 
cell attenuated apo-A4 expression (Supplementary Fig. S4A,B). Based on these results, we proved that NF-κB 
regulates apo-A4.
We showed that inflammatory damage induced TNFR2 activation via NF-κB in human kidney cell lines 
and tissues, and this finding is supported by the fact that the promoter region of TNFR2 contains binding sites 
Figure 5. Inflammatory AKI increases apo-A4 expression through the NF-κB complex. (A) Western blotting 
revealed an inverse relationship between apo-A4 and IκB protein expression in HK-2 cells following TNF-α 
treatment. The loading control was GAPDH and the normalized ratio of each extract pair (A set to 1) determined 
using Image Jv1.42q software (http://rsb.info.nih.gov/ij). (B) Immunofluorescence assay for apo-A4 and NF-κB 
expression in HK-2 cells after 24-h TNF-α treatment. TNF-α antibody was used to neutralize the TNF-α effect. 
NF-κB (green) immune-localization is shown. And NF-κB regulates apo-A4 (see Supplementary Fig. S4).
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for some transcription factors, including NF-κB. Taken together our results proposed that inflammatory AKI 
induced by TNF-α increases apo-A4 expression via the TNFR2-NFκB pathway (Fig. 6A).
Furthermore, we suggest that continuous kidney damage induced by inflammatory AKI disrupts apo-A4 
metabolism, which promotes apo-A4 deposition in kidney cells, possibly leading to irreversible kidney injury 
or amyloidosis4. The mechanisms of apo-A4 function and metabolism in injured kidney tubular cells, however, 
remain unclear (Fig. 6B). Also, the factor that causes apo-A4 deposition during CKD requires identification3, 4, 13. 
Further investigation is needed to determine whether the protective role of apo-A4 is specific to NF-κB, and our 
results provide encouragement for further examinations of the therapeutic effects of apo-A4 in injured kidney 
cells.
In summary, we demonstrated that apo-A4 expression is increased by stimulation of injured kidney cells and 
tissues with TNF-α and that these effects occur via a TNFR2-NF-κB complex.
Materials and Methods
Human Tissues. Normal or ischemic human renal specimens were collected with the informed con-
sent of patients according to the Institutional Review Board at Yonsei University (College of Medicine, Yonsei 
University), and the study was approved by the ethics committee. All human kidney biopsies were stored in liquid 
nitrogen.
Animal Models. The study was approved by the Institutional Animal Care and Use Committee of Yonsei 
University Health System in accordance with the ‘Guide for the Care and Use of Laboratory Animals’ pub-
lished by the National Institutes of Health and was conducted according to the principles of the Declaration 
of Helsinki(2015–0149). Eight-week-old male Sprague-Dawley rats were used for the renal ischemic reperfu-
sion injury model. For the single kidney model, we performed right nephrectomy, and we initiated left kid-
ney ischemia using renal hilar clamping for 30 min followed by reperfusion. Rats were sacrificed 48 h after 
ischemia-reperfusion of the kidney, and kidney tissues and blood samples were collected and stored in liquid 
nitrogen7.
Cell Culture. HK-2 cells were cultured in keratinocyte serum-free medium (K-SFM, Gibco, Grand Island, NY, 
USA) including 0.05 mg/ml bovine pituitary extract, 5 ng/ml human recombinant epidermal growth factor, 10% 
fetal bovine serum, and 1% penicillin/streptomycin under an atmosphere of 5% CO2 and 95% O2 at 37 °C. Cells 
were subcultured every 7 days using 0.02% ethylenediaminetetraacetic acid and 0.05% trypsin. The medium was 
replaced with fresh medium every 2 days.
Western blot. Total cellular protein extracts were prepared on ice using a PRO-PREP protein extract solution 
(Intron, Seoul, Korea). Cell lysates were loaded onto a sodium dodecyl sulfate-polyacrylamide gel and transferred 
to polyvinylidene fluoride membrane for 1 hour. Membranes were incubated at 4 °C overnight with HIF-1α, 
apo-A4, TNFR2, IκB, and α-tubulin primary antibodies (Abcam, Cambridge, MA, USA) diluted 1:1000 with 5% 
BSA Tris-buffered saline-Tween 20 (TBS-T). After incubation, the membranes were washed with TBS-T and then 
secondary antibodies (1:10000, horseradish peroxidase-conjugated anti-mouse IgG, anti-rabbit IgG) were added 
for incubation at room temperature for 1 hour. Labeled bands were detected by West Pico chemiluminescent kit 
(Thermo Scientific, Rockford, IL, USA).
Immunofluorescence Assay. Cells were washed in phosphate-buffered saline (PBS) and fixed in 4% par-
aformaldehyde. Cells were subjected to permeation in 0.5% Triton X-100/ PBS for 5 min and then blocked in 5% 
BSA/PBS for 20 min. Cells were then incubated with mouse anti-apo-A4 antibody (Abcam) at 37 °C for 1 h and 
then incubated with Alexa Fluor 488 anti-mouse secondary antibody (1:200, Invitrogen) at 4 °C for 1 h. Images 
Figure 6. Proposed model of apo-A4 mediated signaling pathway in kidney injury. (A) TNF-α mediates an 
increase in apo-A4 expression during inflammatory AKI. TNF-α activates apo-A4 expression via the TNFR2-
NFκB pathway. (B) Continuous kidney damage caused by ischemic reperfusion injury promotes apo-A4 
deposition in kidney cells.
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were acquired by confocal microscope (LSM Meta 700, Carl Zeiss, Oberkochen, Germany) and analyzed with 
LSM Image Browser software.
IHC. Kidney tissue sections were incubated in formalin and treated overnight with 0.1 M citrate buffer antigen 
retrieval solution (pH 6.0; Dako, Carpinteria, CA, US) at 85 °C. Endogenous peroxidase was blocked with 3% 
H2O2 for 5 min. After blocking in 1% BSA in Tris-HCl buffer (BSA-T, pH 8.6) for 1 h, sections were incubated with 
the anti-human apo-A4 primary antibody (Abcam) diluted 1:400 in BSA-T for 1 h at room temperature. Then, 
specific immunoreaction was detected using a secondary horseradish peroxidase–conjugated goat anti-rabbit 
antibody (Dako). After washing in Tris-HCl buffer, 3-3-diaminbenzidine tetrahydrochloride (DAB + , Dako) was 
used for visualization. Sections were counterstained with hematoxylin, dehydrated, mounted in DePeX (Serva, 
Heidelberg, Germany), and examined with a microscope.
ELISA. Rat plasma apo-A4 concentrations were determined using a double-antibody ELISA. The amounts 
of apo-A4 in the rat plasma were estimated using the apo-A4 rat ELISA kit (Mybiosource, Vancouver, Canada) 
according to the manufacturer’s instructions.
Statistical analysis. Quantitative values were expressed as mean ± S.E.M. Statistical differences were 
compared using the Kruskal-Wallis test and Mann-Whitney U-test with SPSS software version 23.0 (IBM SPSS 
Statistics, IBM Corp., Armonk, N.Y., United States). P < 0.05 was considered statistically significant.
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